Breast cancer molecular subtypes respond differently to preoperative chemotherapy

Clinical Cancer Research

Volumn 11, Issue 16, 2005, Pages 5678-5685

  Rouzier, Roman ^a,b   Perou, Charles M ^c   Symmans, W Fraser ^a   Ibrahim, Nuhad ^a   Cristofanilli, Massimo ^a   Anderson, Keith ^a   Hess, Kenneth R ^a   Stec, James ^d,e   Ayers, Mark ^d   Wagner, Peter ^a   Morandi, Paolo ^a   Fan, Chang ^c   Rabiul, Islam ^a   Ross, Jeffrey S ^d   Hortobagyi, Gabriel N ^a   Pusztai, Lajos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; MOLECULAR MARKER; PACLITAXEL;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CELL NUCLEUS; CLINICAL FEATURE; CONFIDENCE INTERVAL; DNA MICROARRAY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; BREAST; BREAST NEOPLASMS; CLUSTER ANALYSIS; DOXORUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; RECEPTOR, ERBB-2;

EID: 23844549918     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2421     Document Type: Article

References (15)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
3. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
4. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100:10393-8.
5. Symmans WF, Ayers M, Clark EA, et al. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 2003;97:2960-71.
6. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-93.
7. Stec J, Wang J, Coombes K, et al. Comparison of the predictive accuracy of DNA array based multigene classifiers across cDNA arrays and Affymetrix Gene-Chips. J Mol Diagnostics. In press 2005.
8. Cutler SJ, Black MM, Mork T, et al. Further observations on prognostic factors in cancer of the female breast. Cancer 1969;24:653-67.
9. McShane LM, Radmacher MD, Freidlin B, et al. Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data. Bioinformatics 2002;18:1462-9.
10. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
11. Mathieu MC, Rouzier R, Llombart-Cussac A, et al. The poor responsiveness of infiltrating tabular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 2004;40:342-51.
12. Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002;20:1304-10.
13. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9.
14. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer. ASCO Annual Meeting Proceedings 2004;22:501.
15. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.